AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London

Rhea-AI Summary

Atai Beckley (NASDAQ: ATAI) will participate in the Jefferies Global Healthcare Conference in London.

Who: Srinivas Rao, M.D., Ph.D., CEO, and Kevin Craig, M.D., CMO. Format: Fireside chat and one-on-one investor meetings. When: Fireside chat on Thursday, November 20, 2025 at 11:30 A.M. GMT / 6:30 A.M. ET. Webcast: A live webcast is provided and an archived replay will be available on the company Investors Events page for up to 90 days.

News Market Reaction

-4.62%

1 alert

-4.62% News Effect

-$73M Valuation Impact

$1.50B Market Cap

3K Volume

On the day this news was published, ATAI declined 4.62%, reflecting a moderate negative market reaction. This price movement removed approximately $73M from the company's valuation, bringing the market cap to $1.50B at that time.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK and AMSTERDAM, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Atai Beckley N.V. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments, today announced that Srinivas Rao, M.D., Ph.D., Co-Founder and Chief Executive Officer, and Kevin Craig, M.D., Chief Medical Officer, are scheduled to participate in the Jefferies Global Healthcare Conference in London, UK. Details of the company’s participation:

Format: Fireside chat and 1x1 investor meetings
Date and Time: Fireside chat on Thursday, November 20 at 11:30 A.M. GMT/ 6:30 A.M. ET
Webcast link: Here

An archived replay will be available on the Investors section of the AtaiBeckley website under Events for up to 90 days.

About Atai Beckley N.V.
AtaiBeckley is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting and convenient mental health treatments. It was formed through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025. AtaiBeckley’s pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (buccal film DMT) for TRD and EMP-01 (oral R-MDMA) for social anxiety disorder, which are in Phase 2 clinical development. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD. These programs aim to create new possibilities in mental health by providing effective, commercially scalable and convenient interventional psychiatry therapies that can integrate seamlessly into healthcare systems.

For the latest updates and to learn more about the AtaiBeckley mission, visit www.ataibeckley.com or follow the Company on LinkedIn and on X.

Contact Information
Investor Contact:
IR@ataibeckley.com

Media Contact:
PR@ataibeckley.com

FAQ

When will Atai Beckley (ATAI) speak at the Jefferies Global Healthcare Conference?

The fireside chat is scheduled for Thursday, November 20, 2025 at 11:30 A.M. GMT / 6:30 A.M. ET.

Who from Atai Beckley (ATAI) will present at the Jefferies London conference?

Srinivas Rao, M.D., Ph.D., CEO, and Kevin Craig, M.D., CMO will participate.

How can investors watch Atai Beckley (ATAI) at Jefferies Global Healthcare Conference?

A live webcast will be available and an archived replay will be posted on the company's Investors Events page for up to 90 days.

Will Atai Beckley (ATAI) hold investor meetings at the conference?

Yes, the company will conduct one-on-one investor meetings in addition to the fireside chat.

Where will the archived replay of Atai Beckley (ATAI) presentation be hosted?

The replay will be available under Events in the Investors section of the Atai Beckley website for up to 90 days.